Germany
· Delayed Price · Currency is EUR | Market Cap | 732.99M |
| Revenue (ttm) | 535.18M |
| Net Income (ttm) | 162.19M |
| Shares Out | n/a |
| EPS (ttm) | 0.72 |
| PE Ratio | 4.52 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,837 |
| Average Volume | 90,148 |
| Open | 3.242 |
| Previous Close | 3.220 |
| Day's Range | 3.194 - 3.260 |
| 52-Week Range | 2.000 - 4.808 |
| Beta | 2.43 |
| RSI | 62.36 |
| Earnings Date | Apr 25, 2025 |
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In additi... [Read more]
Financial Performance
Financial StatementsNews
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion
BioNTech SE (NASDAQ: BNTX) on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02 . The COVID-19 va...
CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript
CureVac BV reports Q4 results
CureVac N.V. 2024 Q4 - Results - Earnings Call Presentation
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate TransformationCompleted enrollment of Part B of Phase 1 glioblastoma study with investigational precisio...
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precisi...
CureVac: 2024 Financial Results & Business Update Unveiled
CureVac is making strides in medical innovation, with promising studies and robust financial growth marking a transformative year. Jetzt den vollständigen Artikel lesen
EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Issuer: CureVac / Key word(s): Annual Results CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update 10.04.2025 / 13:12 CET/CEST The issuer is solel...
Earnings Scheduled For April 10, 2025
Companies Reporting Before The Bell • CureVac (NASDAQ: CVAC) is likely to report quarterly loss at $0.09 per share on revenue of $20.58 million. • CarMax (NYSE: KMX) is projected to report quarterly...
Insights Ahead: CureVac's Quarterly Earnings
CureVac (NASDAQ: CVAC) is set to give its latest quarterly earnings report on Thursday, 2025-04-10. Here's what investors need to know before the announcement. Analysts estimate that CureVac will rep...
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...
CureVac's 2024 Financial Results & Key Updates: April 10 Reveal
Discover CureVac's 2024 financial insights on April 10, 2025, as the mRNA pioneer shares its global achievements and future outlook. Jetzt den vollständigen Artikel lesen
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
Issuer: CureVac / Key word(s): Annual Results CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025 08.04.2025 / 13:00 CET/CEST The issuer is sole...
CureVac to initiate Phase 1 trial for its lung cancer therapy
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancerProprietary Epitopes: CVHNLC encodes novel...
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes nove...
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Issuer: CureVac / Key word(s): Study/Regulatory Approval CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small C...
CureVac: Patent Win Notable, But Won't Answer More Fundamental Questions
CureVac Shares Rise on Patent Confirmation Amid BioNTech Lawsuit
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. (NASDAQ: CVAC) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protect...
European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps
CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.
European Patent Office declares CureVac mRNA patent valid
The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.
CureVac up 13% as court upholds validity of patent in BioNTech spat
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended formA hearing on infringement of EP 3...